2024. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s489. DOI:https://doi.org/10.25251/skin.8.supp.489.